NU 641 Advanced Pharmacology - QUIZ 1:
PRINCIPLES & CARDIOVASCULAR APPLICATIONS -
Prescriptive Authority Mastery with Rationales
PART 1: CORE PRINCIPLES (Questions 1-7)
Question 1:
A 68-year-old male with atrial fibrillation is started on amiodarone. He has mild hepatic
steatosis but normal renal function. His other medications include warfarin and
atorvastatin. After 2 weeks, his INR increases from 2.5 to 4.8 without bleeding. The
primary mechanism for this interaction is:
A) Amiodarone induces CYP2C9, increasing warfarin metabolism
B) Amiodarone inhibits CYP2C9 and CYP3A4, reducing warfarin clearance
C) Amiodarone displaces warfarin from albumin binding sites
D) Amiodarone increases vitamin K absorption, antagonizing warfarin
Correct Answer: B
Complete Solution:
Core Principle: CYP450 Enzyme Inhibition and Polypharmacy in Hepatic Metabolism
Mechanism-Based Analysis:
● Drug Mechanism: Amiodarone is a potent, non-specific inhibitor of multiple
CYP450 enzymes, particularly CYP2C9 (primary warfarin metabolizing enzyme)
, and CYP3A4. It also inhibits P-glycoprotein. Amiodarone's own metabolism
produces an active metabolite (desethylamiodarone) that continues enzyme
inhibition.
● Patient Factor: Hepatic steatosis may further impair drug metabolism, though
amiodarone itself causes hepatic accumulation (Vd ~5000 L, highly lipophilic).
● Clinical Goal: Recognize that amiodarone-warfarin interaction is predictable,
dose-dependent, and requires preemptive warfarin dose reduction (typically
30-50%).
Justification: The interaction is pharmacokinetic via enzyme inhibition, not protein
displacement or pharmacodynamic antagonism. The 2-week delay corresponds to
amiodarone's long half-life (40-55 days) and time to steady-state inhibition.
Distractor Deconstruction:
● A: Amiodarone is an inhibitor, not inducer; induction would decrease INR.
● C: Warfarin is 99% protein bound, but displacement interactions are transient and
less clinically significant than enzyme inhibition.
● D: Amiodarone does not affect vitamin K absorption or synthesis; this describes
a nutritional interaction, not a drug-drug interaction.
Question 2 (SATA):
A clinical trial compares two new antihypertensive agents. Drug A has an EC50 of 10
mg and produces a maximum reduction of 40 mm Hg systolic. Drug B has an EC50 of
25 mg and produces a maximum reduction of 40 mm Hg systolic. Which statements
accurately interpret these findings? Select all that apply.
A) Drug A is more potent than Drug B
B) Drug A is more efficacious than Drug B
C) Both drugs are full agonists at their target receptor
D) Drug B requires a higher dose to achieve 50% of its maximum effect
,E) If the drugs act at the same receptor, they have identical intrinsic activity
F) Drug A has a higher affinity for the receptor than Drug B
Correct Answers: A, D, E, F
Complete Solution:
Core Principle: Pharmacodynamic Quantification—Potency vs. Efficacy
Mechanism-Based Analysis:
● EC50 Definition: The concentration producing 50% of maximum
response—inverse measure of potency (lower EC50 = higher potency).
● Emax Definition: Maximum achievable response—measure of efficacy (intrinsic
activity).
● Data Interpretation: Both drugs achieve identical Emax (40 mm Hg), indicating
equal efficacy/intrinsic activity. Drug A's lower EC50 indicates higher potency
(achieves same effect at lower concentration).
Justification: This tests understanding that potency (EC50) and efficacy (Emax) are
independent properties. The identical Emax suggests both are full agonists with
identical intrinsic activity; Drug A simply binds with higher affinity.
Distractor Deconstruction:
● B: Incorrect—efficacy is identical (40 mm Hg max). Potency differs, not efficacy.
● C: Cannot conclude they are full agonists without knowing the system's
maximum possible response; they could be partial agonists in a different
context.
Question 3:
A 45-year-old female with epilepsy has been seizure-free on phenytoin for 5 years. She
is diagnosed with latent tuberculosis and started on rifampin. Two weeks later, she has
a breakthrough seizure. The most likely explanation is:
, A) Rifampin inhibits phenytoin metabolism, causing toxicity
B) Rifampin induces hepatic enzymes, increasing phenytoin clearance
C) Rifampin displaces phenytoin from plasma proteins, increasing free fraction
D) Phenytoin auto-induction has reached maximal effect, requiring dose increase
Correct Answer: B
Complete Solution:
Core Principle: CYP450 Enzyme Induction and Time-Dependent Pharmacokinetics
Mechanism-Based Analysis:
● Drug Mechanism: Rifampin is the most potent CYP450 inducer known, affecting
CYP1A2, 2C9, 2C19, 2D6, and 3A4. It activates the pregnane X receptor (PXR),
increasing enzyme synthesis.
● Time Course: Enzyme induction requires 3-7 days for new protein synthesis
(explaining the 2-week delay). This contrasts with inhibition, which is immediate.
● Patient Factor: Phenytoin has narrow therapeutic index (10-20 mcg/mL) and is
metabolized primarily by CYP2C9/2C19—isoforms highly sensitive to rifampin
induction.
● Clinical Goal: Recognize that rifampin-phenytoin interaction requires preemptive
phenytoin dose increase (typically 50-100%) and therapeutic drug monitoring.
Justification: The temporal pattern (2 weeks) and clinical outcome (breakthrough
seizure, not toxicity) confirm induction, not inhibition.
Distractor Deconstruction:
● A: Inhibition would cause toxicity, not seizures; also, rifampin is an inducer, not
inhibitor.
● C: While phenytoin is protein bound (90%), displacement would transiently
increase free drug, not reduce overall levels.
PRINCIPLES & CARDIOVASCULAR APPLICATIONS -
Prescriptive Authority Mastery with Rationales
PART 1: CORE PRINCIPLES (Questions 1-7)
Question 1:
A 68-year-old male with atrial fibrillation is started on amiodarone. He has mild hepatic
steatosis but normal renal function. His other medications include warfarin and
atorvastatin. After 2 weeks, his INR increases from 2.5 to 4.8 without bleeding. The
primary mechanism for this interaction is:
A) Amiodarone induces CYP2C9, increasing warfarin metabolism
B) Amiodarone inhibits CYP2C9 and CYP3A4, reducing warfarin clearance
C) Amiodarone displaces warfarin from albumin binding sites
D) Amiodarone increases vitamin K absorption, antagonizing warfarin
Correct Answer: B
Complete Solution:
Core Principle: CYP450 Enzyme Inhibition and Polypharmacy in Hepatic Metabolism
Mechanism-Based Analysis:
● Drug Mechanism: Amiodarone is a potent, non-specific inhibitor of multiple
CYP450 enzymes, particularly CYP2C9 (primary warfarin metabolizing enzyme)
, and CYP3A4. It also inhibits P-glycoprotein. Amiodarone's own metabolism
produces an active metabolite (desethylamiodarone) that continues enzyme
inhibition.
● Patient Factor: Hepatic steatosis may further impair drug metabolism, though
amiodarone itself causes hepatic accumulation (Vd ~5000 L, highly lipophilic).
● Clinical Goal: Recognize that amiodarone-warfarin interaction is predictable,
dose-dependent, and requires preemptive warfarin dose reduction (typically
30-50%).
Justification: The interaction is pharmacokinetic via enzyme inhibition, not protein
displacement or pharmacodynamic antagonism. The 2-week delay corresponds to
amiodarone's long half-life (40-55 days) and time to steady-state inhibition.
Distractor Deconstruction:
● A: Amiodarone is an inhibitor, not inducer; induction would decrease INR.
● C: Warfarin is 99% protein bound, but displacement interactions are transient and
less clinically significant than enzyme inhibition.
● D: Amiodarone does not affect vitamin K absorption or synthesis; this describes
a nutritional interaction, not a drug-drug interaction.
Question 2 (SATA):
A clinical trial compares two new antihypertensive agents. Drug A has an EC50 of 10
mg and produces a maximum reduction of 40 mm Hg systolic. Drug B has an EC50 of
25 mg and produces a maximum reduction of 40 mm Hg systolic. Which statements
accurately interpret these findings? Select all that apply.
A) Drug A is more potent than Drug B
B) Drug A is more efficacious than Drug B
C) Both drugs are full agonists at their target receptor
D) Drug B requires a higher dose to achieve 50% of its maximum effect
,E) If the drugs act at the same receptor, they have identical intrinsic activity
F) Drug A has a higher affinity for the receptor than Drug B
Correct Answers: A, D, E, F
Complete Solution:
Core Principle: Pharmacodynamic Quantification—Potency vs. Efficacy
Mechanism-Based Analysis:
● EC50 Definition: The concentration producing 50% of maximum
response—inverse measure of potency (lower EC50 = higher potency).
● Emax Definition: Maximum achievable response—measure of efficacy (intrinsic
activity).
● Data Interpretation: Both drugs achieve identical Emax (40 mm Hg), indicating
equal efficacy/intrinsic activity. Drug A's lower EC50 indicates higher potency
(achieves same effect at lower concentration).
Justification: This tests understanding that potency (EC50) and efficacy (Emax) are
independent properties. The identical Emax suggests both are full agonists with
identical intrinsic activity; Drug A simply binds with higher affinity.
Distractor Deconstruction:
● B: Incorrect—efficacy is identical (40 mm Hg max). Potency differs, not efficacy.
● C: Cannot conclude they are full agonists without knowing the system's
maximum possible response; they could be partial agonists in a different
context.
Question 3:
A 45-year-old female with epilepsy has been seizure-free on phenytoin for 5 years. She
is diagnosed with latent tuberculosis and started on rifampin. Two weeks later, she has
a breakthrough seizure. The most likely explanation is:
, A) Rifampin inhibits phenytoin metabolism, causing toxicity
B) Rifampin induces hepatic enzymes, increasing phenytoin clearance
C) Rifampin displaces phenytoin from plasma proteins, increasing free fraction
D) Phenytoin auto-induction has reached maximal effect, requiring dose increase
Correct Answer: B
Complete Solution:
Core Principle: CYP450 Enzyme Induction and Time-Dependent Pharmacokinetics
Mechanism-Based Analysis:
● Drug Mechanism: Rifampin is the most potent CYP450 inducer known, affecting
CYP1A2, 2C9, 2C19, 2D6, and 3A4. It activates the pregnane X receptor (PXR),
increasing enzyme synthesis.
● Time Course: Enzyme induction requires 3-7 days for new protein synthesis
(explaining the 2-week delay). This contrasts with inhibition, which is immediate.
● Patient Factor: Phenytoin has narrow therapeutic index (10-20 mcg/mL) and is
metabolized primarily by CYP2C9/2C19—isoforms highly sensitive to rifampin
induction.
● Clinical Goal: Recognize that rifampin-phenytoin interaction requires preemptive
phenytoin dose increase (typically 50-100%) and therapeutic drug monitoring.
Justification: The temporal pattern (2 weeks) and clinical outcome (breakthrough
seizure, not toxicity) confirm induction, not inhibition.
Distractor Deconstruction:
● A: Inhibition would cause toxicity, not seizures; also, rifampin is an inducer, not
inhibitor.
● C: While phenytoin is protein bound (90%), displacement would transiently
increase free drug, not reduce overall levels.
